Collection: Men's Clothing
-
Men's Wind Breaker Jacket (Embroidered Purple Ribbon)
Regular price From $64.00 USDRegular priceUnit price / per -
Men's Quarter Zip (Embroidered Purple Ribbon)
Regular price From $63.50 USDRegular priceUnit price / perSold out -
Men's Lightweight Zip Hoodie (Embroidered Purple Ribbon)
Regular price From $54.00 USDRegular priceUnit price / per -
Men's Heavy Blend Zip Hoodie (Embroidered Purple Ribbon)
Regular price From $46.50 USDRegular priceUnit price / per -
Men's Columbia Soft Shell Jacket (Embroidered Purple Ribbon)
Regular price From $149.00 USDRegular priceUnit price / per -
Men's Champion Sweatshirt (Purple Ribbon)
Regular price $39.85 USDRegular priceUnit price / per -
Unisex Jersey Short Sleeve Tee
Regular price From $22.55 USDRegular priceUnit price / per
Latest News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...